Gastroenterology
Volume 135, Issue 6 , Pages 1914-1923.e1 , December 2008

Thiazolidinedione Therapy Is Not Associated With Increased Colonic Neoplasia Risk in Patients With Diabetes Mellitus

  • James D. Lewis

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Corresponding Author InformationAddress requests for reprints to: James D. Lewis, MD, MSCE, 720 Blockley Hall, 423 Guardian Drive, Philadelphia, Pennsylvania 19104-6021. fax: (215) 573-0813
    • ,
  • Angela M. Capra

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • ,
  • Ninah S. Achacoso

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • ,
  • Assiamira Ferrara

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • ,
  • Theodore R. Levin

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • ,
  • Charles P. Quesenberry Jr

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California
    • ,
  • Laurel A. Habel

      Affiliations

    • Division of Research, Kaiser Permanente Northern California, Oakland, California

Received 16 May 2008 ,Accepted 4 September 2008.

References 

  1. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:1679–1687
  2. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999;91:1147–1154
  3. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127:1044–1050
  4. Keku TO, Lund PK, Galanko J, et al. Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2005;14:2076–2081
  5. DuBois RN, Gupta R, Brockman J, et al. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis. 1998;19:49–53
  6. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med. 1998;4:1053–1057
  7. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med. 1998;4:1058–1061
  8. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med. 1998;4:1046–1052
  9. Rosenblatt S, Miskin B, Glazer NB, et al. Pioglitazone 026 Study Group The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001;12:413–423
  10. Gibson JM, Westwood M, Crosby SR, et al. Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1995;80:1369–1375
  11. Krishnan A, Nair SA, Pillai MR. Biology of PPAR γ in cancer: a critical review on existing lacunae. Curr Mol Med. 2007;7:532–540
  12. Tanaka T, Kohno H, Yoshitani S, et al. Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 2001;61:2424–2428
  13. Osawa E, Nakajima A, Koichiro W, et al. Peroxisome proliferator-actived receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology. 2003;124:361–367
  14. Girnun GD, Smith WM, Drori S, et al. APC-dependent suppression of colon carcinogenesis by PPARγ. Proc Natl Acad Sci U S A. 2002;99:13771–13776
  15. Niho N, Takahashi M, Kitamura T, et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res. 2003;63:6090–6095
  16. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf. 2007;16:485–492
  17. Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007;25:1476–1481
  18. Friedman G, Habel L, Boles M, et al. Kaiser Permanente Medical Care Program: Division of Research, Northern California, and Center for Health Research, Northwest Division. In:  Strom BL editors. Pharmacoepidemiology. 3rd ed.. West Sussex: John Wiley & Sons, Ltd; 2000;p. 263–283
  19. Selby JV, Ray GT, Zhang D, et al. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care. 1997;20:1396–1402
  20. Karter AJ, Ferrara A, Liu JY, et al. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287:2519–2527
  21. Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12:88–93
  22. Weiss NS. Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it. Am J Epidemiol. 2003;157:957–961
  23. Palmqvist R, Hallmans G, Rinaldi S, et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut. 2002;50:642–646
  24. Wei EK, Ma J, Pollak MN, et al. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev. 2006;15:750–755
  25. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91:620–625
  26. Probst-Hensch NM, Yuan JM, Stanczyk FZ, et al. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer. 2001;85:1695–1699
  27. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–890
  28. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–1952
  29. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas (Calcium Polyp Prevention Study Group). N Engl J Med. 1999;340:101–107
  30. Lewis JD, Capra AM, Achacoso NS, et al. Medical therapy for diabetes is associated with increased use of lower endoscopy. Pharmacoepidemiol Drug Saf. 2007;16:1195–1202
  31. Lewis JD, Strom BL, Kimmel SE, et al. Predictors of recall of over-the-counter and prescription non-steroidal anti-inflammatory drug exposure. Pharmacoepidemiol Drug Saf. 2006;15:39–45
  32. Yood M, Campbell U, Rothman K, et al. Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf. 2007;16:961–968

 The authors disclose the following: Supported by NIH grant CA102599. Drs Lewis, Habel, Ferrara, and Quesenberry have received research funding from Takeda. Dr Lewis has received research support from GlaxoSmithKline. Drs Habel and Ferrara have received research support from Eli Lilly. Dr Habel has also received research support from Merck.

PII: S0016-5085(08)01667-3

doi: 10.1053/j.gastro.2008.09.004

Gastroenterology
Volume 135, Issue 6 , Pages 1914-1923.e1 , December 2008

Article Tools

* Image Usage & Resolution